<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03462251</url>
  </required_header>
  <id_info>
    <org_study_id>IOM-050371</org_study_id>
    <nct_id>NCT03462251</nct_id>
  </id_info>
  <brief_title>Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line</brief_title>
  <acronym>RIBBIT</acronym>
  <official_title>A Randomized, Open-label, Multicenter, Two-arm, Phase III Study to Evaluate Efficacy and Quality of Life in Patients With Metastatic Hormone Receptor-positive HER2-negative Breast Cancer Receiving Ribociclib in Combination With Endocrine Therapy or Chemotherapy With or Without Bevacizumab in First Line</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the efficacy and safety of first-line treatment ribociclib&#xD;
      in combination with aromatase inhibitor (AI) or fulvestrant OR capecitabine with bevacizumab&#xD;
      OR paclitaxel with / without bevacizumab in patients with HR-positive, HER2-negative advanced&#xD;
      breast cancer with visceral metastasis.&#xD;
&#xD;
      Half of the patients will receive a combination of ribociclib and AI/fulvestrant while the&#xD;
      other half will receive capecitabine + bevacizumab or paclitaxel +/- bevacizumab.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, open-label, two-arm, multicenter, interventional phase III&#xD;
      trial in Germany. The study will include adult women with HR-positive, HER2-negative advanced&#xD;
      breast cancer with visceral metastases, who received no prior therapy for advanced disease.&#xD;
&#xD;
      158 patients will be enrolled and randomized 1:1 (stratified by the presence of lung and / or&#xD;
      liver metastases) to receive Arm A: a combination of ribociclib and AI or fulvestrant; OR Arm&#xD;
      B: capecitabine + bevacizumab OR paclitaxel +/- bevacizumab&#xD;
&#xD;
      Treatment will be continued until disease progression, intolerable toxicity or death.&#xD;
      Progression-free survival (PFS) will be based on tumor assessments by local&#xD;
      radiologists/investigator using RECIST v1.1 criteria. Treatment might be continued beyond&#xD;
      RECIST-defined progressive disease (PD) in case of negligible or clinically irrelevant&#xD;
      disease progression according to the investigator's discretion until clinically relevant&#xD;
      disease progression or symptomatic deterioration.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 24, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy in terms of PFS</measure>
    <time_frame>Up to approximately 15 months.</time_frame>
    <description>PFS is defined as time from randomization to progression of disease or death of any cause, whichever comes first. It will be assessed by imaging until progressive disease or start of next-line therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to approximately 48 months.</time_frame>
    <description>OS is defined as time from randomization to death of any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Up to approximately 15 months.</time_frame>
    <description>ORR is defined as the proportion of patients with best overall response of complete or partial response according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>Up to approximately 15 months</time_frame>
    <description>CBR is defined as the proportion of patients with best overall response of complete or partial response or stable disease lasting 24 weeks or more according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time To Response (TTR)</measure>
    <time_frame>Up to approximately 15 months.</time_frame>
    <description>TTR is defined as time from randomization to first occurrence of any response (complete or partial) according to RECIST 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Adverse Events</measure>
    <time_frame>Until 30 days after end of treatment, up to approximately 16 months.</time_frame>
    <description>Type, frequency and severity (according to CTCAE v4.03) of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to deterioration of ECOG performance status</measure>
    <time_frame>Until 30 days after end of treatment, up to approximately 16 months</time_frame>
    <description>Time to deterioration of ECOG performance status by at least one point from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability of treatment</measure>
    <time_frame>Until 30 days after end of treatment, up to approximately 16 months.</time_frame>
    <description>By-patient listings of safety laboratory (hemoglobin, platelets, white blood cells with differentials, international normalized ratio , serum creatinine, bilirubin, Alanine-Aminotransferase (ALT) and Aspartate-Aminotransferase (AST)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>corrected QT interval (QTc) time</measure>
    <time_frame>Until 30 days after end of treatment, up to approximately 16 months.</time_frame>
    <description>By-patient listings of cardiac monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (QoL)</measure>
    <time_frame>Up to 36 months.</time_frame>
    <description>Health-related QoL will be assessed with the EORTC Quality of life questionnaire (QLQ) QLQ-C30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side effects of treatment</measure>
    <time_frame>Up to 36 months.</time_frame>
    <description>One question on treatment burden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time spent on treatment</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Burden by treatment will be assessed with 4 questions on time spent on treatment</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Symptomatic PFS (sPFS)</measure>
    <time_frame>Up to approximately 15 months.</time_frame>
    <description>sPFS is defined as time from randomization until symptomatic deterioration (new or worsening of persisting symptoms) or death as per local investigator.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Hormone Receptor Positive Tumor</condition>
  <condition>HER 2 Negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of ribociclib and aromatase inhibitor or fulvestrant</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Ribociclib and aromatase inhibitor or fulvestrant</intervention_name>
    <description>Combination of ribociclib and aromatase inhibitor or fulvestrant</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Capecitabine + bevacizumab OR Paclitaxel +/- bevacizumab</intervention_name>
    <description>Capecitabine with bevacizumab OR Paclitaxel with or without bevacizumab</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Any menopausal status. If pre-/perimenopausal, agreement to receive LHRH agonist&#xD;
             (goserelin or leuprorelin) / ovarian ablation in case of randomization to arm A&#xD;
&#xD;
          -  Locally confirmed diagnosis of metastatic adenocarcinoma of the breast without prior&#xD;
             systemic antineoplastic therapy in the palliative setting.&#xD;
&#xD;
          -  Hormone receptor (HR)-positive disease, defined as estrogen receptor (ER)-positive&#xD;
             and/or progesterone receptor (PgR)-positive.&#xD;
&#xD;
          -  Human epidermal growth factor receptor 2 (HER2)-negative disease (defined as&#xD;
             immunohistochemistry (IHC) status HER2 negative/+ or IHC HER2++ with chromosomal in&#xD;
             situ hybridization (CISH)/fluorescent in situ hybridization (FISH) negative).&#xD;
&#xD;
          -  Presence of visceral metastases (additional non-visceral metastases are allowed).&#xD;
&#xD;
          -  Presence of target and / or non-target lesions according to RECIST v1.1&#xD;
&#xD;
          -  Patients eligible for palliative treatment with AI / fulvestrant + ribociclib and&#xD;
             capecitabine + bevacizumab or paclitaxel + / - bevacizumab according to the respective&#xD;
             SmPCs.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1.&#xD;
&#xD;
          -  Adequate organ and bone marrow function within 7 days prior to randomization.&#xD;
&#xD;
          -  Standard 12-lead ECG values: QT Interval Corrected by the Fridericia Correction&#xD;
             Formula (QTcF) interval at screening &lt; 450 msec; Mean resting heart rate 50-90 bpm&#xD;
             (determined from the ECG)&#xD;
&#xD;
          -  Signed written informed consent prior to beginning of protocol-specific procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior systemic palliative therapy&#xD;
&#xD;
          -  Prior treatment with any cyclin-dependent kinase 4/6 (CDK4/6) inhibitor.&#xD;
&#xD;
          -  Prior adjuvant or neoadjuvant taxane therapy if last application within 12 months&#xD;
             prior to entering the study.&#xD;
&#xD;
          -  Patient is concurrently using other anti-cancer therapy.&#xD;
&#xD;
          -  Patient has had major surgery within 28 days prior to randomization or has not&#xD;
             recovered from major side effects or wound is not fully recovered.&#xD;
&#xD;
          -  Patient has received extended-field radiotherapy ≤ 4 weeks or limited-field&#xD;
             radiotherapy ≤ 2 weeks prior to randomization.&#xD;
&#xD;
          -  Known hypersensitivity to ribociclib, AI, paclitaxel, bevacizumab or any of their&#xD;
             excipients, or against peanut, soya, Chinese hamster ovarian cell products or&#xD;
             macrogolglycerol ricinoleate-35.&#xD;
&#xD;
          -  Clinically significant, uncontrolled heart disease and/or cardiac repolarization&#xD;
             abnormality (e.g. history of myocardial infarction within 6 months prior study entry,&#xD;
             long QT syndrome, clinically significant cardiac arrhythmias or systolic blood&#xD;
             pressure &gt; 140 or &lt; 90 mmHg or diastolic blood pressure &gt; 90 mmHg).&#xD;
&#xD;
          -  Patient has history of arterial thrombosis within 12 months prior to entering the&#xD;
             study.&#xD;
&#xD;
          -  Patient has proteinuria (≥ 2+ on urine dipstick)&#xD;
&#xD;
          -  Patient with congenital bleeding diathesis, acquired coagulopathy or under full dose&#xD;
             of anticoagulants.&#xD;
&#xD;
          -  Patient is currently receiving strong inducers or inhibitors of CYP3A4/5 or medication&#xD;
             with narrow therapeutic window that are predominantly metabolized through CYP3A4/5 and&#xD;
             cannot be discontinued 7 days prior to start of study treatment.&#xD;
&#xD;
          -  Known presence of cerebral metastases unless at least 4 weeks from prior therapy&#xD;
             completion (including radiation and/or surgery) to starting the study treatment and&#xD;
             clinically stable central nervous system tumor at the time of screening.&#xD;
&#xD;
          -  Patient is currently receiving warfarin or other coumarin derived anti-coagulant, for&#xD;
             treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight&#xD;
             heparin (LMWH), or fondaparinux is allowed.&#xD;
&#xD;
          -  Patient is currently receiving or has received systemic corticosteroids or other&#xD;
             chronic immunosuppressive therapy ≤ 2 weeks prior to starting study drug.&#xD;
&#xD;
          -  Patients with advanced symptomatic, visceral spread, that are at risk of&#xD;
             lifethreatening complications in the short term (including patients with massive&#xD;
             uncontrolled effusions [pleural, pericardial, peritoneal], pulmonary lymphangitis, and&#xD;
             over 50% liver involvement).&#xD;
&#xD;
          -  Patient has a known history of HIV infection (testing not mandatory).&#xD;
&#xD;
          -  Patient has active untreated or uncontrolled fungal, bacterial or viral infection.&#xD;
&#xD;
          -  Patient has any other concurrent severe and/or uncontrolled medical condition that&#xD;
             would, in the investigator's judgment, cause unacceptable safety risks, contraindicate&#xD;
             patient participation in the clinical study or compromise compliance with the protocol&#xD;
             (e.g. chronic pancreatitis, chronic active hepatitis, etc.).&#xD;
&#xD;
          -  Participation in prior investigational studies within 30 days prior to randomization&#xD;
             or within 5-half lives of the investigational product, whichever is longer.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>women (any menopausal status)</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Decker, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gemeinschaftspraxis für Hämatologie und Onkologie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Ravensburg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>88212</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik RWTH Aachen, Gynäkologie und Geburtsmedizin</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Mittelbaden Baden-Baden Balg</name>
      <address>
        <city>Baden-Baden</city>
        <zip>76532</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynäkologisches Zentrum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St.-Johannes-Hospital Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Dortmund</city>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BAG / Onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für interdisziplinäre Onkologie &amp; Hämatologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Überörtliche Berufsausübungsgemeinschaft MVZ Onkologische Kooperation Harz</name>
      <address>
        <city>Goslar</city>
        <zip>38642</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Innere Medizin, Hämatologie, Onkologie, Gastroenterologie</name>
      <address>
        <city>Halle</city>
        <zip>06110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OncoResearch Lerchenfeld GmbH</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IDGGQ GbR</name>
      <address>
        <city>Kaiserslautern</city>
        <zip>67655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämato-Onkologisches Zentrum Kassel MVZ GmbH</name>
      <address>
        <city>Kassel</city>
        <zip>34119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Bettina Peuser</name>
      <address>
        <city>Leipzig</city>
        <zip>04179</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Mühlheim</city>
        <zip>45468</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämatologisch-onkologische Gemeinschaftspraxis</name>
      <address>
        <city>Münster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Dr. med. Jens Uhlig</name>
      <address>
        <city>Naunhof</city>
        <zip>04683</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Neumarkt</name>
      <address>
        <city>Neumarkt</city>
        <zip>92318</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologie Offenburg</name>
      <address>
        <city>Offenburg</city>
        <zip>77654</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis und Tagesklinik für Onkologie und Hämatologie</name>
      <address>
        <city>Recklinghausen</city>
        <zip>45659</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tumorzentrum und Hausarztpraxis Rötha Leipziger-Land</name>
      <address>
        <city>Rötha</city>
        <zip>04571</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis für Hämatologie und Internistische Onkologie, Gastroenterologie</name>
      <address>
        <city>Singen</city>
        <zip>78224</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis</name>
      <address>
        <city>Speyer</city>
        <zip>67346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>g.SUND Gynäkologie Kompetenzzentrum Stralsund</name>
      <address>
        <city>Stralsund</city>
        <zip>18435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH</name>
      <address>
        <city>Villingen-Schwenningen</city>
        <zip>78052</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 12, 2018</study_first_posted>
  <last_update_submitted>March 25, 2021</last_update_submitted>
  <last_update_submitted_qc>March 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>HR positive</keyword>
  <keyword>HER2 negative</keyword>
  <keyword>Mamma carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
    <mesh_term>Aromatase Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

